Drugs patent reforms introduced

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Drugs patent reforms introduced

On September 19 2003, a Decree was published in the Official Gazette of the Federal Government, with amendments to the Regulations of the Health Law as well as to the Regulations of the Law on Industrial Property. The purpose of the amendments is to establish coordination rules between the Ministry of Health and the Mexican Institute of Industrial Property (IMPI), in connection with the granting of pharmaceutical product registrations for marketing approval, when the making and/or selling of the product might trigger the infringement of a patent.

In the case of the Regulations to the Law on Industrial Property, they have been amended, imposing upon IMPI an obligation to publish a special Gazette listing those patents relating to allopathic drugs, and their correspondence to an international non-proprietary name (INN). The catalogue will consider patents that cover "substances or active ingredients", but will exclude other types of patents such as those covering processes.

IMPI has interpreted these amendments, particularly the language "substances and active ingredients" as synonymous. Thus only the patents that cover molecules that could be used as active ingredient in its pure form should be considered to be covered by this publication.

Under this consideration, on November 17 2003 IMPI put into circulation an Extraordinary Gazette, with a list of 89 active ingredients covered by different patents. IMPI is now working on another list of active ingredients covered by patents, which will be published in the next few months.

In the past, due to lack of coordination between IMPI and the Mexican health authorities, a number of registrations relating to products were granted which were covered by patents belonging to parties other than the patentee, producing confusion or conflict. This new regime will be of benefit to patent owners, as from now on the Mexican health authorities will not grant health registrations for products coating the active ingredients as published in the Gazette, until the expiry of the patent.

sanchez-apr04.jpg

Daniel Sánchez

more from across site and SHARED ros bottom lb

More from across our site

Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Practitioners have welcomed extended funding of the specialist police unit until 2029, while the UKIPO says it is exploring increased scale
Abion says integration with Baylos marks an important step in the company’s international expansion plans
Via Licensing Alliance continues its China push as another smartphone manufacturer joins patent pool as licensee
Law firm mergers have the potential to reshape IP teams, and partners who were at the coalface of previous tie-ups say early coordination and flexibility can make the difference
Women are entering the IP profession, but still too few are being trusted with the clients, cases, and credit that may open the path to leadership
In other news, Australia’s IP office has announced expanded search options, and an EPO report shed light on slow progress relating to women inventors in Europe
Managing IP speaks with up-and-coming women lawyers at five law firms about fighting imposter syndrome, maintaining work-life balance and why real representation matters
Gift this article